Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

aHUS

- PMLiVE

Alexion adds to pipeline with $1.2bn Syntimmune buy

As company prepares for possible loss of patent protection for Soliris

- PMLiVE

Alexion uses priority review voucher for Soliris follow-up

Files ravulizumab for paroxysmal nocturnal haemoglobinuria

- PMLiVE

Morning brief: Sanofi’s shaky start, pharma begins talks with UK government and more

Sanofi falling behind in Amgen cholesterol battleFirst quarter results from Sanofi show the company has got off to shaky start in 2018, including signs that it its PCKS9 inhibitor cholesterol...

- PMLiVE

Alexion adds to pipeline rebuild with $855m Wilson buy

Also acquires the Swedish group’s lead product for Wilson’s disease

Shire teams up with Microsoft and EURORDIS for rare disease project

Will work to accelerate the time to diagnosis for children

- PMLiVE

Big data, privacy and the rise of genomic testing

Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Blue Latitude Health

- PMLiVE

Alexion appoints new senior VP for EMEAC region

Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland

- PMLiVE

Alexion’s Soliris gets US approval for myasthenia gravis

New neurology indication could contribute $1.2bn to sales, says analysts

Why I think rare disease companies are more patient-centric

Guest blogger Kamlesh Sheth believes companies that specialise in rare disease tend to be more patient-centric.

Say Communications

- PMLiVE

Germany will be first EU launch market for new Soliris indication

Alexion 'currently evaluating' additional European launches for its orphan drug

- PMLiVE

A Spotlight on Healthcare Communications Advocacy by Alastair Kent

Earlier this year I received an email from Stefi Rucci asking me if I would mind if she nominated me for the Healthcare Advocate of the Year at this year’s...

Say Communications

- PMLiVE

NICE broadens access to Alexion’s rare disease drug Strensiq

New deal offers NHS England a discount for the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links